RecruitingPhase 2NCT07521007

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-controlled Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of YN001 in Adults With Coronary Atherosclerosis

Sponsor

Beijing Inno Medicine Co., Ltd.

Enrollment

456 participants

Start Date

Jul 31, 2026

Study Type

INTERVENTIONAL

Conditions

Atherosclerosis Coronary Artery Disease

Summary

This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called YN001/Placebo 0mg, a drug called YN001/Placebo 20mg, and others for people with atherosclerosis and coronary artery disease. The study is currently recruiting participants at 28 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGYN001/Placebo 40mg

Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

DRUGYN001/Placebo 20mg

YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

DRUGYN001/Placebo 0mg

YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Locations(40)

Heart Center Research, LLC

Huntsville, Alabama, United States

Clinical Trials Research

Lincoln, California, United States

Stanford University School of Medicine

Stanford, California, United States

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Torrance, California, United States

Excel Medical Clinical Trials dba Flourish Research - Boca Raton

Boca Raton, Florida, United States

HCA Florida Heart Institute

Petersburg, Florida, United States

Southern Illinois University School of Medicine

Springfield, Illinois, United States

Midwest Heart & Vascular Specialists

Overland Park, Kansas, United States

Washington University School of Medicine

St Louis, Missouri, United States

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States

The Carl & Edyth Lindner Center for Research & Education at The Christ Hospital

Cincinnati, Ohio, United States

Capital Area Research

Camp Hill, Pennsylvania, United States

Cannopy Clinical Research

Penrith, New South Wales, Australia

Core Research Group Pty Ltd.

Brisbane, Queensland, Australia

Canopy Clinical Research

Altona N., Victoria, Australia

North York Diagnostic and Cardiac Center

North York, Ontario, Canada

Anhui Provincial Hospital

Hefei, Anhui, China

The First Affiliated Hospital of Anhui Medical Unversity

Hefei, An, China

Anzhen Hospital

Beijing, Beijing Municipality, China

Beijing Jishuitan Hospital

Beijing, Beijing Municipality, China

Beijing Luhe Hospital

Beijing, Beijing Municipality, China

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

The Second Hospital & Clinical Medical School Lanzhou University

Lanzhou, Gansu, China

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

The First Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, China

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China

The Second Xiangya Hospital fo Central South University

Changsha, Hunan, China

The First Hospital of Jilin University

Changchun, Jilin, China

The People's Hospital of Liaoning Province

Shenyang, Liaoning, China

Shaanxi Provincial People's Hospital

Xi'an, Shaanxi, China

Central Hospital Affiliated to Shandong First Medicial University

Jinan, Shandong, China

Renji Hospital Shanghai Jiaotong University school of medicine

Shanghai, Shanghai Municipality, China

Fudan University-Zhongshan Hospital

Shanghai, Shanghai Municipality, China

West China Hospital of Sichuan University

Chengdu, Sichuan, China

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China

Tianjin People's Hospital

Tianjin, Tianjin Municipality, China

The Second Hospital of Tianjin Medical University

Tianjin, Tianjin Municipality, China

Zhengjiang Provincial People's Hospital

Hangzhou, Zhejiang, China

The First Affiliated Hospital of Soochow University

Suzhou, Zhejiang, China

The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU

Wenzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07521007

Related Trials

OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation

NCT0541855633 locations

Product Surveillance Registry

NCT01524276400 locations

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

Conditions

Summary

Eligibility

Plain Language Summary

Interventions

Locations(40)

Related Trials

Study of the Effect of Innate on the Inflammatory Response to Endotoxin

Causes and Natural History of Dyslipidemias

MIECC vs Conventional Cardiopulmonary Bypass and Systemic Inflammation in CABG

OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation

Product Surveillance Registry